

# Prognostic implication of post-MitraClip vena contracta area in heart failure patients with functional mitral regurgitation



Hannes Alessandrini<sup>1</sup>, MD; Felix Kreidel<sup>1\*</sup>, MD; Michael Schlüter<sup>2</sup>, PhD; Christian Frerker<sup>1</sup>, MD; Tobias Schmidt<sup>1</sup>, MD; Thomas Thielsen<sup>1</sup>, MD; Ulrich Schäfer<sup>1</sup>, MD; Karl-Heinz Kuck<sup>1</sup>, MD

1. Department of Cardiology, Asklepios Klinik St. Georg, Hamburg, Germany; 2. Asklepios proresearch, Hamburg, Germany

H. Alessandrini and F. Kreidel contributed equally to this manuscript.

This paper also includes supplementary data published online at: [http://www.pcronline.com/eurointervention/113th\\_issue/318](http://www.pcronline.com/eurointervention/113th_issue/318)

## KEYWORDS

- heart failure
- MitraClip
- mitral regurgitation
- vena contracta area

## Abstract

**Aims:** Significant functional mitral regurgitation (FMR) in elderly heart failure patients is increasingly being treated by MitraClip implantation. We sought to assess the prognostic implications of the intraprocedural assessment of vena contracta area (VCA) after MitraClip therapy in such patients.

**Methods and results:** MitraClip therapy with intraprocedural assessment of VCA was performed in 97 heart failure patients (74±10 years; 66 men; left ventricular ejection fraction [LVEF] 31±12%; 93 patients in New York Heart Association [NYHA] functional Class III [n=59] or IV [n=34]; 86 patients with FMR severity 3+ [n=65] or 4+ [n=21]). Ninety-one patients (94%) were discharged with FMR severity ≤2+. During a median follow-up of 13.4 (interquartile range 4.6-21.1) months, 32 patients died. Multivariable Cox regression identified increasing age (HR [95% confidence interval]=1.05 [1.00-1.09], p=0.0395), a glomerular filtration rate <50 ml/min/1.73 m<sup>2</sup> (HR=2.7 [1.3-5.7], p=0.0115), and post-MitraClip VCA >25 mm<sup>2</sup> (HR=4.5 [2.1-9.5], p=0.0001) as independent predictors of mortality.

**Conclusions:** In heart failure patients with FMR undergoing MitraClip therapy, increasing age, impaired baseline renal function and post-MitraClip VCA >25 mm<sup>2</sup> are strongly associated with mortality. Post-MitraClip VCA may be used as intraprocedural guidance with respect to patients' long-term outcome.

\*Corresponding author: Department of Cardiology, Asklepios Klinik St. Georg, Lohmühlenstr. 5, 20099 Hamburg, Germany.  
E-mail: [f.kreidel@asklepios.com](mailto:f.kreidel@asklepios.com)

## Abbreviations

<b>FMR</b>	functional mitral regurgitation
<b>LVEF</b>	left ventricular ejection fraction
<b>MR</b>	mitral regurgitation
<b>TOE</b>	transoesophageal echocardiography
<b>VCA</b>	vena contracta area

## Introduction

Functional mitral regurgitation (FMR) due to ischaemic heart disease or dilated cardiomyopathy is common in patients with chronic congestive heart failure<sup>1</sup>. In heart failure patients with a reduced ejection fraction, the presence and severity of FMR is adversely associated with survival<sup>2-5</sup>. Implantation of the MitraClip® (Abbott Vascular, Santa Clara, CA, USA) has become the most frequently used percutaneous modality to treat significant mitral regurgitation in patients not amenable to surgery. According to the 2012 European Society of Cardiology guidelines for valvular heart disease, "... the percutaneous MitraClip procedure may be considered in patients with symptomatic severe FMR despite optimal medical therapy (including cardiac resynchronisation therapy if indicated), who fulfil the echocardiographic criteria of eligibility, are judged inoperable or at high surgical risk by a team of cardiologists and cardiac surgeons, and who have a life expectancy greater than 1 year..."<sup>6</sup>. Vena contracta area (VCA), measured intraprocedurally by three-dimensional transoesophageal echocardiography (TOE), is a novel variable reflecting the severity of MR: it is directly affected by the intervention and can be determined by the addition of planimetered areas in the presence of multiple regurgitant jets<sup>7-10</sup>. Since about two in three patients undergoing MitraClip therapy in Europe present with FMR and impaired left ventricular function<sup>11</sup>, i.e., constitute essentially a heart failure population, we sought to assess the association of post-MitraClip VCA with mortality in this challenging cohort.

## Methods

### PATIENTS

Of the 192 patients with FMR who underwent MitraClip therapy at our institution between December 2010 and February 2014, only those 97 patients not lost to follow-up in whom VCA was determined before and after the intervention were retrospectively chosen as the study cohort. The mean age of the study patients was 74 years, 68% were men, and all had been adjudicated by Heart Team consensus as inoperable or at high surgical risk (**Table 1**). Of note, 51% of the patients presented with impaired renal function, as reflected by a glomerular filtration rate <50 ml/min/1.73 m<sup>2</sup> (estimated via the Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI] formula), and 84 patients (87%) had impaired left ventricular function with an ejection fraction ≤45%. The vast majority (96%) of the patients were in New York Heart Association (NYHA) functional Class III or IV (**Figure 1**).


**Table 1. Baseline patient characteristics.**

N		97
Men, n (%)		66 (68)
Age, years		74±10
Age >75 years, n (%)		52 (54)
Body mass index (BMI), kg/m <sup>2</sup>		26±5
BMI >25 kg/m <sup>2</sup> , n/N (%)		43/81 (53)
Logistic EuroSCORE, %*		18 [6-36]
Log. EuroSCORE >20%, n/N (%)		48/84 (51)
NT-proBNP, pg/ml*		5,800 [2,697-9,684] (n=53)
CRT, n (%)		27 (28)
ICD therapy, n (%)		22 (23)
LVEDD, mm		64±10
Abnormal LVEDD <sup>#</sup> , n/N (%)		77/95 (81)
LVESD, mm		53±12
Abnormal LVESD <sup>##</sup> , n/N (%)		81/93 (87)
LVEDV, ml		177±77
Abnormal LVEDV <sup>§</sup> , n/N (%)		56/85 (66)
LVESV, ml		177±77
Abnormal LVESV <sup>§§</sup> , n/N (%)		73/85 (86)
LVEF, %		31±12
LVEF <30%, n (%)		54 (56)
LVEF 30-45%, n (%)		30 (31)
LVEF >45%, n (%)		13 (13)
TAPSE, mm		14.6±4.6
TAPSE <17 mm, n/N (%)		55/83 (66)
NYHA functional class, n (%)	II	4 (4)
	III	59 (61)
	IV	34 (35)
Hypertension, n/N (%)		71/89 (80)
Hyperlipidaemia, n/N (%)		56/91 (62)
Diabetes mellitus, n/N (%)		20/91 (22)
COPD, n/N (%)		24/92 (26)
Pulmonary hypertension <sup>¶</sup> , n/N (%)		39/95 (59)
Atrial fibrillation, n/N (%)		63/91 (69)
GFR, ml/min/1.73 m <sup>2</sup>		53±20
GFR <50 ml/min/1.73 m <sup>2</sup> , n (%)		49 (51)
Coronary artery disease, n/N (%)		63/91 (69)
Previous cardiac surgery, n/N (%)		31/91 (34)
Peripheral arterial disease, n/N (%)		16/92 (17)

\*Median [IQR]. <sup>#</sup>>52 mm in women, >58 mm in men; <sup>##</sup>>35 mm in women, >40 mm in men<sup>13</sup>. <sup>§</sup>>106 ml in women, >150 ml in men; <sup>§§</sup>>42 ml in women, >61 ml in men<sup>13</sup>. <sup>¶</sup>Mean pulmonary artery pressure (right heart catheterisation) ≥25 mmHg. COPD: chronic obstructive pulmonary disease; CRT: cardiac resynchronisation therapy; EuroSCORE: European System for Cardiac Operative Risk Evaluation; GFR: glomerular filtration rate; ICD: implantable cardioverter/defibrillator; LVEDD: left ventricular end-diastolic diameter; LVEDV: left ventricular end-diastolic volume; LVEF: left ventricular ejection fraction; LVESD: left ventricular end-systolic diameter; LVESV: left ventricular end-systolic volume; NYHA: New York Heart Association; TAPSE: tricuspid annular plane systolic excursion

### MITRACLIP IMPLANTATION

MitraClip implantations were performed in accordance with a previously described protocol<sup>12</sup>. Procedural success was defined as MR severity ≤2+ at discharge.



**Figure 1.** Distribution of baseline New York Heart Association (NYHA) functional class according to left ventricular ejection fraction (LVEF) category.

## ECHOCARDIOGRAPHY

All patients underwent two-dimensional transthoracic echocardiography (Vivid™ E9; GE Vingmed Ultrasound AS, Horten, Norway, or iE33; Philips Medical Systems, Andover, MA, USA) before and after the intervention. Standard parameters of left ventricular dimension were assessed according to recent guidelines. LVEF was calculated from left ventricular volumes via Simpson's rule, and tricuspid annular plane systolic excursion (TAPSE) served as an assessment of right ventricular function<sup>13,14</sup>. MR severity was graded by way of vena contracta width, effective regurgitant orifice area, and the presence or absence of pulmonary venous flow reversal before MitraClip therapy<sup>15</sup>, and via colour flow Doppler jet area after MitraClip therapy<sup>16</sup> (**Online Table 1**).

Intraprocedural TOE was performed with the iE33 echocardiography system and a corresponding probe (X7-2t). Colour Doppler full volumes of the regurgitant jet were acquired over seven to 10 consecutive cardiac cycles. Nyquist limits were set between 40 and 68 cm/sec; colour gain setting was kept at 50% in all patients. Tissue priority was kept at factory settings. To reduce "stitching" artefacts, patients were put on anaesthesia-controlled breath-hold. In patients with atrial fibrillation, Doppler volumes were acquired during episodes with as little cycle length variation as possible. Care was taken to assess pre- and post-MitraClip MR under similar haemodynamic conditions; when needed, fluid challenges and vasodilators were administered to achieve similar blood pressures.

VCA was assessed as previously described<sup>7-10</sup> using dedicated software (QLAB 8.0; Philips Medical). Before MitraClip therapy, the frame with the largest VCA in early to mid systole (excluding the very first frame) was identified for plane-corrected planimetry<sup>17,18</sup>. In order to assess the cross-sectional area at the neck of the vena contracta precisely, the two orthogonal image planes parallel to the jet direction were manually cropped exactly across the regurgitant jet. The plane perpendicular to the jet direction was then moved along the jet to find the minimum cross-sectional area distal to the regurgitant orifice (**Figure 2**). After MitraClip

implantation, the same approach (i.e., alignment of two orthogonal planes with the regurgitant jet, then finding the smallest cross-sectional area in the third orthogonal plane) was used to measure VCAs for each regurgitant jet; single-jet VCAs were added up to arrive at a final post-MitraClip VCA<sup>10,17</sup>. Very small regurgitant jets with no traceable colour Doppler information at the level of the regurgitant orifice/leaflet tips were not taken into account.

All VCA measurements were performed by two experienced investigators (H. Alessandrini, F. Kreidel). To assess intra-observer variability, both investigators measured post-MitraClip VCAs twice at a three-week interval in 25 randomly selected patients.

## FOLLOW-UP

After hospital discharge, follow-up visits were scheduled at six weeks and 12 months, with annual telephone follow-up conducted thereafter.

## ETHICS

Written informed consent was obtained from all patients.

## STATISTICS


Continuous variables are described as means and standard deviations or as medians plus interquartile range (IQR). Differences between continuous variables were analysed with t-tests (normally distributed data) and the Mann-Whitney U test or Wilcoxon's signed-rank test (non-normally distributed data or markedly unequal group sizes). Three-group comparisons of continuous variables were assessed using one-way analysis of variance. Categorical variables are described with absolute and relative frequencies. Differences between categorical variables were evaluated with the chi-square or Fisher's exact test. Linear regression (Pearson correlation) and Bland-Altman analysis were used to evaluate the relationship and agreement, respectively, between VCA measurements by the two investigators. Intraclass correlation coefficients (ICCs) were calculated to assess the reliability of VCA measurement by the two investigators (two-way mixed model) as well as the reliability of repeated VCA measurement by the same investigator (one-way random model). Patient survival was assessed using the Kaplan-Meier method, log-rank test, and Cox proportional hazards regression analysis. All covariates which were statistically significant ( $p < 0.05$ ) on univariate analysis were entered into a "full" multivariable proportional hazards model that adhered to the "10 events per independent variable" recommendation<sup>19</sup>.

A two-tailed  $p$ -value  $< 0.05$  was considered statistically significant, except for multiple ( $n=3$ ) two-group comparisons, for which  $p < 0.0167$  was considered statistically significant. Statistical analyses utilised the StatView 4.5 (Abacus Concepts, Inc., Berkeley, CA, USA) and SPSS, Version 22 (IBM Corp., Armonk, NY, USA) software packages.

## Results

### PROCEDURAL OUTCOMES

In the course of the 97 interventions, a total of 149 clips were implanted, with 51 patients receiving a single clip, 41 patients




**Figure 2.** Measurement of VCA by 3D TOE before and after MitraClip implantation. A1-A4 illustrate findings before MitraClip implantation. A1: full-volume colour Doppler view of grade 3+ MR. A2: view of regurgitant jet in cut plane aligned with the jet; red and blue lines denote cut planes orthogonal to the one shown. A3: view of regurgitant jet in cut plane denoted by red line in panel A2; green line denotes cut plane shown in panel A2. A4: view of VCA in cut plane shown in panels A2 and A3 as blue line; VCA was 45 mm<sup>2</sup>. B1-B4 and C1-C4 illustrate corresponding findings for lateral (red arrows) and medial regurgitant jet (yellow arrows), respectively, persisting after MitraClip implantation. With lateral jet VCA 5 mm<sup>2</sup> and medial jet VCA 1 mm<sup>2</sup>, total post-MitraClip VCA was 6 mm<sup>2</sup>.

receiving two clips, and five patients receiving three (n=4) or four (n=1) clips. The mean number of regurgitant jets visualised on transthoracic echocardiography in the apical two-chamber view was  $1.2 \pm 0.6$  (range 0-3). Median total device time, i.e., the time from transseptal puncture to withdrawal of the clip delivery system from the left atrium, was 53 (IQR 36-88) minutes. With baseline MR severity predominantly 3+ (n=42) or 4+ (n=41), the interventions resulted in patients being discharged mostly with MR 1+ (n=52) or 2+ (n=39) (**Figure 3**). Procedural failures were encountered in six patients (6.2%).


### VCA MEASUREMENT

With VCA values ranging between 0 and 70 mm<sup>2</sup>, the mean difference between two measurements was  $0.6 \pm 2.8$  mm<sup>2</sup> (ICC=0.986; 95% confidence interval [CI]: 0.969 to 0.994,  $p < 0.0001$ ) for one investigator and  $3.2 \pm 4.5$  mm<sup>2</sup> (ICC=0.817; 95% CI: 0.631 to 0.915,  $p < 0.0001$ ) for the other. Inter-observer variability for all 194 (97 pre- and 97 post-MitraClip) VCA measurements is illustrated in **Figure 4**. Overall correlation between investigators was good (Pearson's  $r = 0.95$ ,  $p < 0.001$ ; ICC=0.949; 95% CI: 0.933 to 0.961,  $p < 0.0001$ ). The Bland-Altman plot revealed a mean bias



**Figure 3.** Distribution of mitral regurgitation (MR) severity at baseline and discharge in the 97 study patients.

close to 0 mm<sup>2</sup> (+1 mm<sup>2</sup> for pre-, -1 mm<sup>2</sup> for post-MitraClip VCA measurements), with markedly lower 95% limits of agreement (-23.5 mm<sup>2</sup> to 21.5 mm<sup>2</sup>) for post-MitraClip measurements.




**Figure 4.** Statistical evaluation of VCA measurements. A) Correlation of VCA measurements by two investigators. Pearson's correlation coefficient is 0.95. B) Bland-Altman plot of pre- (blue circles) and post-MitraClip (red circles) VCA measurements in 97 patients. Solid horizontal lines denote the mean difference in VCA measurements between the two investigators: +1 mm<sup>2</sup> for pre-MC, -1 mm<sup>2</sup> for post-MC measurements. Broken horizontal lines mark the upper and lower 95% limits of agreement ( $\pm 1.96$  standard deviations). MC: MitraClip

The mean VCA between the two investigators was used for all subsequent analyses.

MitraClip implantation resulted in a significant decrease in VCA from 86 (median; IQR 60-108) mm<sup>2</sup> pre-MitraClip to 17 (7-29) mm<sup>2</sup> at the end of the procedure (post-MitraClip;  $p < 0.0001$ ). Post-MitraClip VCA increased with increasing discharge MR grade; however, there was pronounced overlap of VCA values between MR grades (Figure 5).

#### FOLLOW-UP

With two patients lost to follow-up, 95 patients were followed for a median of 13.4 (IQR 4.6-21.1) months. During follow-up, a total of 32 patients died at a median of 408 (IQR 141-642) days post-MitraClip (29 [33%] of 89 successfully, three of six unsuccessfully treated patients). The cause of death could not be determined in four patients; 24 patients died of cardiac reasons at



**Figure 5.** Box plots of post-MitraClip VCA according to MR severity at discharge.

a median of 130 (50-360) days, and the other four patients died of non-cardiac reasons at a median of 57 (26-292) days ( $p = 0.32$ ). Latest post-MitraClip functional status was assessed in 43 of the 63 surviving, successfully treated patients at a median of 18 (14-27) months. At that time, 28 patients (65%) were in NYHA functional Class I or II, with improvement in NYHA class noted in 31 patients (72%), no change in 10 patients (23%), and worsening in two (5%).

To assess predictors of mortality, pertinent procedural, clinical and echocardiographic variables were tested in univariate Cox proportional hazards models. Increasing age, a logistic EuroSCORE  $> 20\%$ , impaired renal function at baseline, the presence of peripheral arterial disease, and a post-MitraClip VCA  $> 25$  mm<sup>2</sup> turned out to be predictive of mortality. Notably, impaired LVEF ( $\leq 45\%$ ), NYHA functional Class IV and discharge MR severity did not impact on mortality (Table 2). With no apparent differential impact of the lower two post-MitraClip VCA terciles on mortality (hazard ratio [HR] 0.9,  $p = 0.88$ ), and since the logistic EuroSCORE incorporates age, post-MitraClip VCA dichotomised at 25 mm<sup>2</sup>, age, impaired baseline renal function and peripheral arterial disease were tested in a multivariable proportional hazards model. Increasing age, post-MitraClip VCA  $> 25$  mm<sup>2</sup> and impaired renal function prevailed as statistically significant, independent predictors of mortality, with HRs of 1.05 ( $p = 0.0395$ ), 4.5 ( $p = 0.0001$ ) and 2.7 ( $p = 0.0115$ ), respectively (Table 2).

To illustrate the association of post-MitraClip VCA with survival, Figure 6 shows a statistically significant difference ( $p = 0.0005$ ) between survival curves according to terciles of post-MitraClip VCA. *Post hoc* two-group comparisons revealed no difference in survival between patients in the lower vs. the middle post-MitraClip VCA tercile ( $< 10$  mm<sup>2</sup> vs. 10-25 mm<sup>2</sup>,  $p = 0.83$ ), but statistically significant differences in survival between patients in the middle vs. the upper tercile (10-25 mm<sup>2</sup> vs.  $> 25$  mm<sup>2</sup>,  $p = 0.0015$ ), and between patients in the lower vs. the upper tercile ( $< 10$  mm<sup>2</sup> vs.  $> 25$  mm<sup>2</sup>,  $p = 0.0028$ ). Survival estimates are given in Online Table 2.

**Table 2. Predictors of mortality.**


	Univariate analysis		Multivariable* analysis	
	HR (95% CI)	p-value	HR (95% CI)	p-value
<b>Procedural</b>				
Procedural failure	1.7 (0.5-5.6)	0.39		
<b>Clinical</b>				
Female gender	0.7 (0.3-1.5)	0.37		
Age, years	1.05 (1.00-1.09)	0.0344	1.05 (1.00-1.09)	0.0395
BMI >25 kg/m <sup>2</sup>	0.7 (0.4-1.4)	0.34		
Logistic EuroSCORE >20%	2.22 (1.1-4.7)	0.0340		
Hypertension	0.7 (0.3-1.5)	0.35		
Hyperlipidaemia	0.9 (0.5-1.9)	0.84		
Diabetes	1.2 (0.5-2.6)	0.70		
COPD	1.6 (0.8-3.5)	0.20		
Pulmonary hypertension <sup>†</sup>	1.6 (0.8-3.2)	0.22		
Atrial fibrillation	1.1 (0.4-2.0)	0.82		
Impaired renal function <sup>‡</sup>	2.4 (1.2-4.9)	0.0197	2.7 (1.3-5.7)	0.0115
Coronary artery disease	1.2 (0.6-2.8)	0.61		
Previous cardiac surgery	1.7 (0.9-3.4)	0.13		
Peripheral arterial disease	2.2 (1.0-4.8)	0.0447	1.9 (0.8-4.3)	0.12
CRT	0.7 (0.3-1.5)	0.34		
NYHA IV (vs. II/III)	1.6 (0.8-3.3)	0.16		
<b>Echocardiographic</b>				
Abnormal LVEDD <sup>§</sup>	0.9 (0.4-2.1)	0.77		
Abnormal LVESD <sup>¶</sup>	1.2 (0.4-3.4)	0.76		
Abnormal LVEDV <sup>§</sup>	0.8 (0.4-1.6)	0.45		
Abnormal LVESV <sup>§§</sup>	1.1 (0.4-3.2)	0.87		
LVEF <30% (vs. >45%)	1.1 (0.4-2.9)	0.93		
LVEF 30-45% (vs. >45%)	0.8 (0.3-2.4)	0.66		
Pre-MC TAPSE <17 mm	2.4 (1.0-5.9)	0.06		
Discharge MR 1+/2+ (vs. 3+)	0.6 (0.2-2.0)	0.39		
Discharge MR 2+ (vs. 1+)	1.0 (0.5-2.2)	0.95		
Pre-MC VCA ≥86 mm <sup>2</sup>	0.8 (0.4-1.7)	0.61		
Post-MC VCA				
>25 mm <sup>2</sup> vs. ≤10 mm <sup>2</sup>	3.6 (1.5-9.1)	0.0055		
10-25 mm <sup>2</sup> vs. ≤10 mm <sup>2</sup>	0.9 (0.3-2.9)	0.88		
>25 mm <sup>2</sup> vs. ≤25 mm <sup>2</sup>	3.8 (1.9-7.8)	0.0003	4.5 (2.1-9.5)	0.0001

\*Full model of covariates found statistically significant on univariate analysis. Logistic EuroSCORE not included as it includes age. <sup>†</sup>>52 mm in women, >58 mm in men; <sup>‡</sup>>35 mm in women, >40 mm in men<sup>13</sup>. <sup>§</sup>>106 ml in women, >150 ml in men; <sup>§§</sup>>42 ml in women, >61 ml in men<sup>13</sup>. <sup>‡</sup> Glomerular filtration rate (CKD-EPI formula) <50 ml/min/1.73 m<sup>2</sup>. <sup>†</sup> Mean pulmonary artery pressure (right heart catheterisation) ≥25 mmHg. CI: confidence interval; COPD: chronic obstructive pulmonary disease; CRT: cardiac resynchronisation therapy; HR: hazard ratio; LVEDD: left ventricular end-diastolic diameter; LVEDV: left ventricular end-diastolic volume; LVEF: left ventricular ejection fraction; LVESD: left ventricular end-systolic diameter; LVESV: left ventricular end-systolic volume; MC: MitraClip; MR: mitral regurgitation; PAP: pulmonary artery pressure; TAPSE: tricuspid annular plane systolic excursion

## Discussion

### MAJOR FINDINGS

Unique to this single-centre study of 97 heart failure patients with predominantly moderate-to-severe (3+) or severe (4+) FMR is the finding of a strong association of mortality with post-MitraClip VCA. Compared with patients in whom VCA was ≤25 mm<sup>2</sup> after



**Figure 6.** Cumulative survival curves in 95 patients according to tertiles of post-MitraClip VCA. Log-rank  $p=0.0005$  indicates overall difference between survival curves. MC: MitraClip

MitraClip implantation, the likelihood of death during follow-up was increased by a factor of 4.5 in patients with a post-MitraClip VCA >25 mm<sup>2</sup>. The only other covariates independently and strongly predictive of mortality were increasing age and impaired baseline renal function, defined as a glomerular filtration rate <50 ml/min/1.73 m<sup>2</sup>.

Functional assessment in 43 of our patients at a median of 18 months after successful MitraClip implantation revealed that 72% had improved from baseline, such that roughly two thirds were in NYHA functional Class I or II at that time point.

The primary intention of our study was to assess whether three-dimensional VCA as a fairly easily acquired parameter is of prognostic value. A previous study found that a reduction in VCA by >50% was associated with a smaller annulus area pre-MitraClip and a greater reduction in atrial and ventricular volumes six months post-MitraClip<sup>17</sup>, but, to the best of our knowledge, a VCA of 25 mm<sup>2</sup> has never been discussed as a marker of procedural success.

### PREDICTORS OF MORTALITY AFTER MITRACLIP THERAPY

Of note, in our study, baseline LVEF and baseline NYHA functional class were not associated with mortality after MitraClip therapy. These covariates were found to predict mortality in the German TRAMI (n=749) and the Italian GRASP-IT (n=304) registries<sup>20,21</sup>. However, it must be realised that almost all of our patients had impaired left ventricular function (mean LVEF 31%, n=84 with LVEF ≤45%) and that almost all presented with heart failure symptoms of NYHA functional Class III or IV. Apparently, in this patient cohort, minor variations in LVEF towards the better or the worse did not affect mortality. NYHA functional Class III at the time of the intervention, as opposed to NYHA Class IV, appeared to be beneficial in terms of survival only for the first year after treatment and thus corresponds to the finding of Franzen and co-workers<sup>22</sup>. By two years, however, that benefit was lost in our patients.

Both the TRAMI and GRASP-IT registries identified procedural failure as predictive of mortality<sup>20,21</sup>. With a procedural failure rate of only 6.2% in the 97 patients of our study, an association between procedural outcome and mortality was not apparent.

### CLINICAL RELEVANCE

The presence of MR in heart failure patients has been shown to impact adversely on the patients' prognosis: in particular, mortality was directly associated with the severity of MR<sup>2-5</sup>. In our study, however, we did not observe an association with mortality of discharge MR severity assessed by regurgitant colour flow jet area. Apparently, post-MitraClip MR grade as determined via that variable is not a reliable representation of the true severity of residual MR.

Since VCA can be measured during the procedure, post-MitraClip VCA assessment may become a means to indicate whether the number of clips implanted is sufficient in terms of prognosis or not. In our patients, a post-MitraClip VCA >25 mm<sup>2</sup> was associated with a poor prognosis. Although it is tempting to consider a post-MitraClip VCA of 25 mm<sup>2</sup> as a cut-off that discriminates patients with a favourable prognosis from those with a poor prognosis, it must be realised that grouping of patients by terciles is arbitrary. The 25 mm<sup>2</sup> value represents the upper limit of the middle tercile (i.e., the 67th percentile of the total post-MitraClip VCA distribution) in our cohort of 97 patients; the uncertainty when considering 25 mm<sup>2</sup> as a generally valid cut-off is reflected by a 95% confidence interval ranging from 21 to 30 mm<sup>2</sup>. Therefore, greater numbers of patients are needed to confirm the clinical validity of the 25 mm<sup>2</sup> post-MitraClip VCA cut-off.

### Limitations

Patients in this retrospective single-centre study were not enrolled consecutively but rather based on the availability of i) VCA measurements pre and post MitraClip therapy, and ii) follow-up information. The study did not involve an independent echocardiographic core laboratory. The presence or absence of reverse remodelling and its prognostic impact were not assessed, and the velocity time integral across the mitral valve was not measured; therefore, regurgitant volumes could not be calculated retrospectively. The number of patients studied was not high enough for a narrow 95% confidence interval associated with the 25 mm<sup>2</sup> post-MitraClip VCA cut-off. Validation of a prognostically relevant cut-off would require a separate patient population.

### Conclusions

In heart failure patients undergoing MitraClip therapy for significant functional MR, we have introduced the "new" quantitative echocardiographic variable of post-MitraClip VCA to assess prognosis. Post-MitraClip VCA may lend itself as a tool to guide interventional decision making with respect to the patient's long-term outcome. Our findings require prospective validation in larger patient cohorts.

### Impact on daily practice

Intraprocedural measurement of VCA by 3D TOE may be helpful to assess the acute outcome of MitraClip implantation.

### Conflict of interest statement

U. Schäfer and K-H. Kuck have received research grants from Abbott Vascular. The other authors have no conflicts of interest to declare.

### References

1. Trichon BH, O'Connor CM. Secondary mitral and tricuspid regurgitation accompanying left ventricular systolic dysfunction: is it important, and how is it treated? *Am Heart J.* 2002;144:373-6.
2. Koelling TM, Aaronson KD, Cody RJ, Bach DS, Armstrong WF. Prognostic significance of mitral regurgitation and tricuspid regurgitation in patients with left ventricular systolic dysfunction. *Am Heart J.* 2002;144:524-9.
3. Trichon BH, Felker GM, Shaw LK, Cabell CH, O'Connor CM. Relation of frequency and severity of mitral regurgitation to survival among patients with left ventricular systolic dysfunction and heart failure. *Am J Cardiol.* 2003;91:538-43.
4. Bursi F, Enriquez-Sarano M, Nkomo VT, Jacobsen SJ, Weston SA, Meverden RA, Roger VL. Heart failure and death after myocardial infarction in the community: the emerging role of mitral regurgitation. *Circulation.* 2005;111:295-301.
5. Rossi A, Dini FL, Faggiano P, Agricola E, Cicoira M, Frattini S, Simioniuc A, Gullace M, Ghio S, Enriquez-Sarano M, Temporelli PL. Independent prognostic value of functional mitral regurgitation in patients with heart failure. A quantitative analysis of 1256 patients with ischaemic and non-ischaemic dilated cardiomyopathy. *Heart.* 2011;97:1675-80.
6. Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC); European Association for Cardio-Thoracic Surgery (EACTS), Vahanian A, Alfieri O, Andreotti F, Antunes MJ, Barón-Esquivias G, Baumgartner H, Borger MA, Carrel TP, De Bonis M, Evangelista A, Falk V, Jung B, Lancellotti P, Pierard L, Price S, Schäfers HJ, Schuler G, Stepinska J, Swedberg K, Takkenberg J, Von Oppell UO, Windecker S, Zamorano JL, Zembala M. Guidelines on the management of valvular heart disease (version 2012). *Eur Heart J.* 2012;33:2451-96.
7. Little SH, Pirat B, Kumar R, Igo SR, McCulloch M, Hartley CJ, Xu J, Zoghbi WA. Three-dimensional color Doppler echocardiography for direct measurement of vena contracta area in mitral regurgitation: in vitro validation and clinical experience. *JACC Cardiovasc Imaging.* 2008;1:695-704.
8. Yosefy C, Hung J, Chua S, Vaturi M, Ton-Nu TT, Handschumacher MD, Levine RA. Direct measurement of vena contracta area by real-time 3-dimensional echocardiography for assessing severity of mitral regurgitation. *Am J Cardiol.* 2009;104:978-83.
9. Zeng X, Levine RA, Hua L, Morris EL, Kang Y, Flaherty M, Morgan NV, Hung J. Diagnostic value of vena contracta area in the

quantification of mitral regurgitation severity by color Doppler 3D echocardiography. *Circ Cardiovasc Imaging*. 2011;4:506-13.

10. Hyodo E, Iwata S, Tugcu A, Arai K, Shimada K, Muro T, Yoshikawa J, Yoshiyama M, Gillam LD, Hahn RT, Di Tullio MR, Homma S. Direct measurement of multiple vena contracta areas for assessing the severity of mitral regurgitation using 3D TEE. *JACC Cardiovasc Imaging*. 2012;5:669-76.

11. Maisano F, Franzen O, Baldus S, Schäfer U, Hausleiter J, Butter C, Ussia GP, Sievert H, Richardt G, Widder JD, Moccetti T, Schillinger W. Percutaneous mitral valve interventions in the real world: early and 1-year results from the ACCESS-EU, a prospective, multicenter, nonrandomized post-approval study of the MitraClip therapy in Europe. *J Am Coll Cardiol*. 2013;62:1052-61.

12. Feldman T, Foster E, Glower DD, Kar S, Rinaldi MJ, Fail PS, Smalling RW, Siegel R, Rose GA, Engeron E, Loghini C, Trento A, Skipper ER, Fudge T, Letsou GV, Massaro JM, Mauri L; EVEREST II Investigators. Percutaneous repair or surgery for mitral regurgitation. *N Engl J Med*. 2011;364:1395-406.

13. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, Flachskampf FA, Foster E, Goldstein SA, Kuznetsova T, Lancellotti P, Muraru D, Picard MH, Rietzschel ER, Rudski L, Spencer KT, Tsang W, Voigt JU. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *Eur Heart J Cardiovasc Imaging*. 2015;16:233-70.

14. Rudski LG, Lai WW, Afilalo J, Hua L, Handschumacher MD, Chandrasekaran K, Solomon SD, Louie EK, Schiller NB. Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. *J Am Soc Echocardiogr*. 2010;23:685-713.

15. Zoghbi WA, Enriquez-Sarano M, Foster E, Grayburn PA, Kraft CD, Levine RA, Nihoyannopoulos P, Otto CM, Quinones MA, Rakowski H, Stewart WJ, Waggoner A, Weissman NJ; American Society of Echocardiography. Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography. *J Am Soc Echocardiogr*. 2003;16:777-802.

16. Foster E, Wasserman HS, Gray W, Homma S, Di Tullio MR, Rodriguez L, Stewart WJ, Whitlow P, Block P, Martin R, Merlino J, Herrmann HC, Wieggers SE, Silvestry FE, Hamilton A, Zunamon A,

Kraybill K, Gerber IL, Weeks SG, Zhang Y, Feldman T. Quantitative assessment of severity of mitral regurgitation by serial echocardiography in a multicenter clinical trial of percutaneous mitral valve repair. *Am J Cardiol*. 2007;100:1577-83.

17. Altiok E, Hamada S, Brehmer K, Kuhr K, Reith S, Becker M, Schröder J, Almalla M, Lehmacher W, Marx N, Hoffmann R. Analysis of procedural effects of percutaneous edge-to-edge mitral valve repair by 2D and 3D echocardiography. *Circ Cardiovasc Imaging*. 2012;5:748-55.

18. Kahlert P, Plicht B, Schenk IM, Janosi RA, Erbel R, Buck T. Direct assessment of size and shape of noncircular vena contracta area in functional versus organic mitral regurgitation using real-time three-dimensional echocardiography. *J Am Soc Echocardiogr*. 2008;21:912-21.

19. Peduzzi P, Concato J, Feinstein AR, Holford TR. Importance of events per independent variable in proportional hazards regression analysis. II. Accuracy and precision of regression estimates. *J Clin Epidemiol*. 1995;48:1503-10.

20. Puls M, Lubos E, Boekstegers P, von Bardeleben RS, Ouarrak T, Butter C, Zuern CS, Bekeredjian R, Sievert H, Nickenig G, Eggebrecht H, Senges J, Schillinger W. One-year outcomes and predictors of mortality after MitraClip therapy in contemporary clinical practice: results from the German transcatheter mitral valve interventions registry. *Eur Heart J*. 2016;37:703-12.

21. Capodanno D, Adamo M, Barbanti M, Giannini C, Laudisa ML, Cannata S, Curello S, Immè S, Maffeo D, Bedogni F, Petronio AS, Etori F, Tamburino C, Grasso C; GRASP-IT Investigators. Predictors of clinical outcomes after edge-to-edge percutaneous mitral valve repair. *Am Heart J*. 2015;170:187-95.

22. Franzen O, van der Heyden J, Baldus S, Schlüter M, Schillinger W, Butter C, Hoffmann R, Corti R, Pedrazzini G, Swaans MJ, Neuss M, Rudolph V, Sürder D, Grünenfelder J, Eulenburg C, Reichenspurner H, Meinertz T, Auricchio A. MitraClip® therapy in patients with end-stage systolic heart failure. *Eur J Heart Fail*. 2011;13:569-76.

## Supplementary data

**Online Table 1.** Grading of functional MR severity by transthoracic echocardiography before and after MitraClip therapy.

**Online Table 2.** Kaplan-Meier estimates of survival.

The supplementary data are published online at:

<http://www.pcronline.com/>

[eurointervention/113th\\_issue/318](http://www.pcronline.com/eurointervention/113th_issue/318)



## Supplementary data

**Online Table 1. Grading of functional MR severity by transthoracic echocardiography before and after MitraClip therapy.**

Before MitraClip therapy		
2+	3+	4+
VC width <7 mm AND EROA <20 mm <sup>2</sup>	(VC width ≥7 mm OR EROA ≥20 mm <sup>2</sup> ); NO Systolic PV flow reversal	(VC width ≥7 mm OR EROA ≥20 mm <sup>2</sup> ) AND Systolic PV flow reversal
EROA determined via proximal isovelocity surface area (PISA) method; VC width measured in apical 3-chamber view.		
After MitraClip therapy		
2+	3+	4+
CFD jet area <4 cm <sup>2</sup>	CFD jet area 4-6 cm <sup>2</sup>	CFD jet area >6 cm <sup>2</sup>
CFD jet areas assessed in apical 2-chamber view and summed in cases of multiple jets.		
CFD: colour flow Doppler; EROA: effective regurgitant orifice area; PV: pulmonary vein; VC: vena contracta		

**Online Table 2. Kaplan-Meier estimates of survival.**

	30 days (%)	6 months (%)	1 year (%)	2 years (%)
All patients (n=95 initially at risk)	96.8 [93.3-100]	80.8 [72.9-88.8]	75.9 [67.0-84.7]	63.1 [51.7-74.6]
Patients with post-MC VCA <10 mm <sup>2</sup> (n=30 initially at risk)	93.3 [84.4-100]	86.5 [74.3-98.8]	82.4 [68.3-96.5]	76.9 [60.1-93.7]
Patients with post-MC VCA 10-25 mm <sup>2</sup> (n=33 initially at risk)	100 [100-100]	87.4 [75.8-99.0]	83.9 [70.9-96.9]	83.9 [70.9-96.9]
Patients with post-MC VCA >25 mm <sup>2</sup> (n=32 initially at risk)	96.8 [85.4-100]	68.8 [52.7-84.8]	61.9 [44.8-78.9]	33.1 [13.7-52.5]
[ ]: 95% confidence interval. MC: MitraClip				